Prevention and treatment of Candida infections in neonates

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Mycology

Background:

• Invasive Candida infections are the third leading cause of late-onset infection in very low birth weight infants.
• Key risk factors include low birth weight, broad-spectrum antibiotic exposure, and central venous catheter use.
• Candida albicans and C. parapsilosis are common, but non-albicans species are increasing.

Purpose of the Study:

• To review current understanding of neonatal invasive Candida infections.
• To discuss therapeutic options including standard and novel antifungal agents.
• To evaluate the role and potential risks of antifungal chemoprophylaxis.

Main Methods:

• Literature review of invasive Candida infections in neonates.
• Analysis of risk factors, causative species, and treatment strategies.
• Examination of studies on antifungal prophylaxis, primarily fluconazole.

Main Results:

• Standard therapy includes amphotericin B; fluconazole shows similar efficacy in some trials.
• Newer agents like voriconazole and echinocandins offer potential treatment improvements.
• Fluconazole prophylaxis effectively reduces fungal colonization and infection but may select for resistant strains.

Conclusions:

• Neonatal invasive Candida infections require careful management with evolving therapeutic options.
• Antifungal prophylaxis is effective but requires further multicenter trials to address potential harms like resistance.
• Continued research into novel antifungals and prophylaxis strategies is crucial for improving outcomes.